Angeliki Malliri

University of Manchester — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

35h-index4.9kcitations86works2.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Kinase Regulation and GTPase Signaling(19), Cancer-related Molecular Pathways(15), Ubiquitin and proteasome pathways(14), Cellular Mechanics and Interactions(12), Cell Adhesion Molecules Research(9)

Publications86 total

Correction: A stretchable and biomimetic polyurethane membrane for lung alveolar in vitro modelling
Scientific Reports·2026Open Access
Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-refractory KRAS G12C-mutant NSCLC for Immune Checkpoint Blockade
Cancer Discovery·2026Open Access
P-Rex1 limits the agonist-induced internalization of GPCRs independently of its Rac-GEF activity
Cell Reports·2025Open Access
1992P Targeting KRAS codon 13 mutations using combinations with RMC-8839, a novel RAS(ON) G13C-selective, tri-complex inhibitor, in non-small cell lung cancer
Annals of Oncology·2025
Meeting reports
The Biochemist·2025Open Access
A stretchable and biomimetic polyurethane membrane for lung alveolar in vitro modelling
Scientific Reports·2025· 3 citedOpen Access
A stretchable and biomimetic polyurethane membrane for lung alveolar <i>in vitro</i> modelling
2024· 1 citedOpen Access
The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer
Molecular Cancer·2024· 22 citedOpen Access
113 (PB101): Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer
European Journal of Cancer·2024
Abstract 2494: RAS-Bio a unique pan-cancer biobank for RAS-driven tumors
Cancer Research·2024
Abstract 1443: The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer
Cancer Research·2024
POTEE promotes breast cancer cell malignancy by inducing invadopodia formation through the activation of SUMOylated Rac1
Molecular Oncology·2023· 4 citedOpen Access
Author response for "POTEE promotes breast cancer cell malignancy by inducing invadopodia formation through the activation of SUMOylated Rac1"
2023
The Rac-GEF Tiam1 controls integrin-dependent neutrophil responses
Frontiers in Immunology·2023· 6 citedOpen Access
Author response for "POTEE promotes breast cancer cell malignancy by inducing invadopodia formation through the activation of SUMOylated Rac1"
2023
2253P RAS-precision medicine trans-atlantic partnership: Comparative analysis of KRAS codon 12 and 13 mutations in non-small cell lung cancer
Annals of Oncology·2023· 1 citedOpen Access
2254P Persisting RAS addiction: A therapeutic vulnerability in the context of KRAS G12C inhibitor resistance
Annals of Oncology·2023Open Access
A TIAM1-TRIM28 complex mediates epigenetic silencing of protocadherins to promote migration of lung cancer cells
Proceedings of the National Academy of Sciences·2023· 34 citedOpen Access
The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRAS <sup>G12D</sup> -driven non-small cell lung cancer
2023Open Access
Dock2 generates characteristic spatiotemporal patterns of Rac activity to regulate neutrophil polarisation, migration and phagocytosis
Frontiers in Immunology·2023· 9 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Gavin White(9), Andrew P. Porter(7), John G. Collard(6), Owen J. Sansom(6), John K. Field(6), Adam Hurlstone(6), Demetrios�� Spandidos(5), Sonia Castillo‐Lluva(5), Natalie A. Mack(4), Hadir Marei(4), Simon A. Woodcock(4), Zoi Diamantopoulou(4), Chong Teik Tan(4), Fiona Blackhall(4), Rob A. van der Kammen(3), Helen J. Whalley(3), Richard C. Jones(3), Claire Rooney(3), Kurt I. Anderson(3), Joe Maltas(3)